Fitbits and glucose monitors tested for exercise tracking in cancer and diabetes patients

NCT ID NCT05124405

Ongoing Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether people with cancer or diabetes can use a Fitbit and a continuous glucose monitor (CGM) to track their daily exercise and glucose levels. The goal is to see if it's practical and if people will stick with it. Thirty-five participants will wear both devices for a period of time, and researchers will measure how many people agree to join and how well they follow the monitoring plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fitbit and continuous glucose monitor (CGM)
What this could lead to: If successful, this could show that wearable devices are a practical way to monitor physical activity and glucose levels in people with cancer or diabetes.
What could go wrong: This is a very small feasibility study with only 35 participants. It is not designed to test health outcomes, only whether people will use the devices as instructed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer cancer colorectal cancer diabetes mellitus neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER DIABETES

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.